Introduction
• Understand the mechanism of action of Mounjaro, a once-weekly, first-in-class GIP and GLP-1 receptor agonist for chronic weight management and type 2 diabetes.
• Review the efficacy and safety of Mounjaro in chronic weight management and type 2 diabetes.
• Review the efficacy superiority of Mounjaro (Tirzepatide) compared with Wegovy (Semaglutide) in chronic weight management.
• Discuss the safe and effective use of Mounjaro.
Objectives
• Understand the mechanism of action of Mounjaro, a once-weekly, first-in-class GIP and GLP-1 receptor agonist for chronic weight management and type 2 diabetes.
• Review the efficacy and safety of Mounjaro in chronic weight management and type 2 diabetes.
• Review the efficacy superiority of Mounjaro (Tirzepatide) compared with Wegovy (Semaglutide) in chronic weight management.
• Discuss the safe and effective use of Mounjaro.
This Course For :
Clinical Pharmacy
Pharmacy
Speaker
Bassem Mohamed Abdel-Maksoud
Executive Manager, CardioMetabolic at Eli Lilly Saudi Arabia
Price
Course Fee
FREE
FREE
Contact Information
Organization : Virtual Medical AcademyPhone : 920008161
Email : [email protected]
Free
17 Sep 2025 To 17 Sep 2025 -
07:00 PM To 09:00 PM 
Certificate Available 
Online
Add to Calendar
09/17/2025 07:00 PM
09/17/2025 09:00 PM
Asia/ Riyadh
Mounjaro: A Once-Weekly, First-in-Class GIP and GLP-1 Receptor Agonist for Chronic Weight Management and Type 2 Diabetes
Mounjaro: A Once-Weekly, First-in-Class GIP and GLP-1 Receptor Agonist for Chronic Weight Management and Type 2 Diabetes
https://medicalacademy.org/portal/event/view/2449
